1. Home
  2. KNF vs ABCL Comparison

KNF vs ABCL Comparison

Compare KNF & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knife Riv Holding Co.

KNF

Knife Riv Holding Co.

HOLD

Current Price

$53.49

Market Cap

3.5B

Sector

N/A

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$14.27

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNF
ABCL
Founded
1917
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.5B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
KNF
ABCL
Price
$53.49
$14.27
Analyst Decision
Buy
Strong Buy
Analyst Count
8
5
Target Price
★ $97.25
$8.40
AVG Volume (30 Days)
1.0M
★ 4.0M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 10.91
EPS
N/A
★ N/A
Revenue
★ $3,146,012,000.00
$75,128,000.00
Revenue This Year
$8.93
N/A
Revenue Next Year
$5.28
$21.85
P/E Ratio
★ N/A
N/A
Revenue Growth
8.52
★ 160.56
52 Week Low
$50.67
$2.75
52 Week High
$96.28
$14.23

Technical Indicators

Market Signals
Indicator
KNF
ABCL
Relative Strength Index (RSI) 33.05 74.33
Support Level N/A $3.39
Resistance Level $80.57 N/A
Average True Range (ATR) 2.09 0.77
MACD 0.18 0.12
Stochastic Oscillator 33.58 86.57

Price Performance

Historical Comparison
KNF
ABCL

About KNF Knife Riv Holding Co.

Knife River Corp is a people-first construction materials and contracting services company. It provides construction materials and contracting services to build safe roads, bridges, airport runways, and other critical infrastructure needs that connect people. The group is a provider of crushed stone, sand, and gravel in the United States. It operates through four reportable segments: West, Mountain, Central, and Energy Services.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: